Adare Pharma Solutions, a global contract development and manufacturing organization (CDMO) specializing in oral dosage forms, entered a strategic partnership with Laxxon Medical, a pharmaceutical technology company focused on advanced drug delivery solutions. The collaboration aims to leverage Adare’s state-of-the-art cGMP facilities and Laxxon’s innovative 3D printing technology to bring innovative new oral dosage forms to market.
 
The partnership will utilize the Screen-Printed Innovative Drug (SPID) Technology, licensed from Exentis Group, to create customizable, 3D-printed oral dosage forms with precise control over drug release profiles and improved bioavailability. The technology allows for the production of complex formulations with multiple active ingredients and tailored pharmacokinetics.
 
Adare’s Pessano facility in Milan, Italy, has been equipped with a 3D printing system and a new bulk preparation mixer to support the production of these innovative dosage forms. The facility will enable Adare and Laxxon to scale up production from laboratory quantities to clinical trial materials.
 
A second clinical-scale 3D production system is planned for installation at Adare’s Vandalia, Ohio facility at the end of Q4 2024. The addition of clinical-scale machines at facilities in Europe and North America will give Adare and Laxxon proximity to the two largest pharmaceutical markets for this innovative technology.
 
Tom Sellig, CEO of Adare Pharma Solutions said, “Our Pessano facility provides comprehensive CDMO solutions to customers in Europe, the United States, and Asia. Adare’s collaboration with Laxxon expands our ability to provide incredible dose flexibility options such as taste masking, solubility enhancement, shape modifications for ease of swallowing, and multiple APIs.”
 
“Laxxon’s partnership with Adare represents a significant step forward in actualizing our mission to drive disruptive global drug delivery and manufacturing solutions,” Helmut Kerschbaumer, CEO of Laxxon Medical, said. “This is an essential collaboration for Laxxon; Adare, with their CDMO expertise and state-of-the-art cGMP facilities, will enable us to produce clinical samples for our partners as well as our own internal pipeline.”
 
The SPID Technology platform offers a unique approach to 3D printing, allowing for the production of multi-compartment tablets with customizable release profiles and improved bioavailability. The technology has the potential to revolutionize the way certain drugs are delivered, providing patients with more effective and convenient treatment options.